Hypokalemia Measurement and Management in Patients With Status Asthmaticus on Continuous Albuterol

OBJECTIVE: Status asthmaticus is commonly treated in pediatric patients by using continuous albuterol, which can cause hypokalemia. The primary aim of this study was to determine if serial potassium monitoring is necessary by examining treatment frequency of hypokalemia. METHODS: This retrospective analysis was performed in 185 pediatric patients admitted with status asthmaticus requiring continuous albuterol between 2017 and 2019. All patients were placed on intravenous fluids containing potassium. The primary outcome measure was the treatment of hypokalemia in relation to the number of laboratory draws for potassium levels. The secondary outcome measure was hypokalemia frequency and relation to the duration and initial dose of continuous albuterol. RESULTS: Included were 156 patients with 420 laboratory draws (average, 2.7 per patient) for potassium levels. The median lowest potassium level was 3.40 mmol/L (interquartile range, 3.2–3.7). No correlation was found between initial albuterol dose and lowest potassium level (P = .52). Patients with hypokalemia had a mean albuterol time of 12.32 (SD, 15.76) hours, whereas patients without hypokalemia had a mean albuterol time of 11.50 (SD, 12.53) hours (P = .29). Potassium levels were treated 13 separate times. CONCLUSIONS: The number of laboratory draws for potassium levels was high in our cohort, with few patients receiving treatment for hypokalemia beyond the potassium routinely added to maintenance fluids. Length of time on albuterol and dose of albuterol were not shown to increase the risk of hypokalemia. Serial laboratory measurements may be decreased to potentially reduce health care costs, pain, and anxiety surrounding needlesticks.

Safety Comparison of Conventional Versus Extended Infusion of Pulse Methylprednisolone in Multiple Sclerosis Exacerbation Retrospective Study

Objective: - To ascertain the adverse events and changes in vital signs (heart rate (HR), systolic (SBP), diastolic blood pressure (DBP), and serum potassium level during and after intravenous methylprednisolone (IVMP) in multiple sclerosis exacerbation.Design: retrospective review study conducted at Hamad General Hospital (HGH), all patients who are admitted 2019-2020 with MS exacerbation without any other comorbidities will be categorized into 2 groups depending on infusion rate, one group received conventional intravenous methylprednisolone pulse dose over 30minutes to one hour, while the second group received methylprednisolone pulse dose intravenously over an extended period)(four to six hours). Multiple readings of vital signs and, potassium level through steroid administration time will be assessed to determine if there is an infusion-related significant difference in adverse events between both groups.Methods: 74 adult patients with MS relapse who have been admitted at Hamad General Hospital (HGH) and satisfied pre-specified inclusion criteria were invited to participate in the study.Results: 74 patients with MS included in the study, 61 patients (83.6%) were received methylprednisolone dose 500 mg -1000 mg in conventional infusion rate while 12 patients (16.4%) were received pulse steroid in extended duration. There was no significant difference in mean blood pressure before and after IVMP in both groups. There was a small but statistically significant increase in mean heart rate in the conventional group immediately after first and second but not 3rd dose of IVMP compared to baseline 3.5± 8.9 and 4.85± 13.9 P < 0.003. There was a minimal non-significant increase in potassium level in the conventional group (P = 0.17), while there is a non-significant decrease in potassium level in the extended group (P=0.72).Conclusion: IVMP is considered safe and effective in the treatment of MS exacerbation regardless of intravenous infusion duration. There was no significant difference in vital signs among different infusion rates. However, there was a small but statistically significant increase in mean heart rate in the conventional group immediately after first and second but not 3rd dose of IVMP compared to baseline. No significant difference was observed in potassium levels before and after IVMP. We, therefore, recommend that potassium level monitoring should be only restricted to patients with other risk factors of hypokalemia.

ANALYSIS OF POTENTIAL INTERACTIONS OF RAMIPRIL -AMBON BANANA (Musa paradisiaca var. sapientum (L.) Kunt.) ON HYPERKALEMIA RISK IN WHITE RATS

Introduction: Drug and food interaction is a condition in which nutritional factors present in food have an influence significant effect on drug therapy, both potentially increasing or decreasing the effect of drug therapy. Indonesian people have a habit of taking medicine by using food or drink. Bananas are the primadona that are often consumed to speed up the swallowing process and reduce the bitter taste of medicine. It turns out that the consumption of bananas together with ACE inhibitors can increase the risk of hyperkalemia. Lack of information about the effects caused by drug and food interactions, so it is necessary to do related research. Objective: This study aims to determine the interaction of giving ramipril together with Ambon banana on the risk of hyperkalemia. Methods: A real experimental study while still adhering to the Covid'19 health protocol. White rats were divided into 4 groups, conditioned by hypertension, then intervened with ramipril and Ambon banana. Blood serum was taken and analyzed using UV spectrophotometry to obtain serum potassium levels. The levels obtained were analyzed using the One Way Anova Test. Results: The mean serum potassium level of the positive control group was 4.93±0.58; negative control 4.13±0.60; normal control 4.76±0.59 and treatment 5.10±0.38. The highest serum potassium level was in the ramipril treatment group together with Ambon banana, but still in the normal range of 3.60–5.50 mmol/L. One Way Anova test results (p = 0.054). (p>0.05) showed no significant difference. Conclusion: There is no specific increase in levels of ramipril concurrently with Ambon banana so it does not have the potential to cause the risk of hyperkalemia. Keywords: Drug Interaction, Ramipril, Ambon Banana, Serum Potassium, Hyperkalemia

Reverse pseudohyperkalemia in a newly diagnosed pediatric patient with acute T-cell leukemia and hyperleukocytosis: a case report and literature review

Background Hyperkalemia is a serious medical condition that requires immediate intervention. However, pseudohyperkalemia and reverse pseudohyperkalemia are misleading clinical manifestations that can result in incorrect diagnosis and consequent harmful intervention. Case presentation An 11-year-old girl manifested an incidental finding of hyperleukocytosis (WBC > 400 × 109/L), with 90% blast cells during routine pre-operative investigations for adenotonsillectomy. Initial investigations demonstrated elevated serum potassium levels (7.5 mmol/L), despite concomitantly normal levels in venous blood gas samples (3.9–4.4 mmol/L) and being clinically stable with normal 12-lead ECG. Surprisingly, plasma potassium level was exacerbated, in comparison to the serum level by > 1 mmol/L. This finding is consistent with reverse pseudohyperkalemia that is associated with hyperleukocytosis in acute leukemia that does not require any active intervention. Conclusion This case report emphasizes the significance of interpreting potassium levels accurately, preferably utilizing whole-blood potassium level over serum and plasma level in newly diagnosed leukemia cases with hyperleukocytosis. Additionally, having a high index for the possibility of reverse pseudohyperkalemia, secondary to leakage from fragile leukocytes, avoids unnecessary treatment that might cause harm to the patient.

Correlation of serum electrolytes with serial miRNA in advanced stage non-small cell lung cancer (NSCLC) in Indonesia

Objective This study aims to evaluate the correlation between electrolytes and serial miRNAs from our previous study. We want to prove that there is the molecular basis that underlying electrolytes disturbances as the predictive indicator to the outcome in NSCLC patients. Results There were positive correlation between potassium level with miR-34 (p = 0.008, r = 0.366), miR-148 (p = 0.004, r = 0.394) and miR-155 (p = 0.031, r = 0.300).

Abiraterone Induced Refractory Hypokalemia and Torsades de Pointes in a Patient with Metastatic Castration-Resistant Prostate Carcinoma: A Case Report

Background Abiraterone, an androgen deprivation therapy (ADT), has been used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It has been associated with increased risks of hypokalemia and cardiac disorders. We report a case of torsades de pointes (TdP) associated with abiraterone use and refractory hypokalemia in a man with mCRPC. Case summary A 78-year-old man with mCRPC presented to the emergency room for generalized weakness. Laboratory results revealed a potassium level of 2.2 mmol/L (3.5-5.0), magnesium level of 2.4 mg/dl (1.6-2.5), and normal kidney and hepatic functions. Initial EKG showed atrial fibrillation with rapid ventricular rate of 106 b.p.m., frequent premature ventricular contractions (PVCs), and a QTc of 634 ms. The patient had multiple episodes of TdP, became pulseless and underwent advanced cardiac life support, including defibrillation. Despite a total of 220 mEq of intravenous potassium chloride, his potassium level only improved to 2.8 mmol/L. He received spironolactone and amiloride to promote urinary potassium reabsorption in addition to hydrocortisone, in an effort to reduce abiraterone’s effect on increasing mineralocorticoid synthesis. Discussion Abiraterone has been widely used in mCRPC since its approval by the FDA in 2011. Regulatory guidelines and standardized close QTc and electrolyte monitoring in patients may help prevent fatal arrhythmias associated with abiraterone.

Preventing transfusion associated hyperkalemia in pediatric cardiac surgery : Measure The Levels of Potassium in Packed Red Blood Cells Before Using – invited Commentary

The authors present an revolutionary study aiming to evaluate the effect of alterations in potassium concentrations in transfused packed red blood cells (PRBC) on neonate and infant potassium levels after congenital cardiac surgery. By establishing a strict protocol which restricts the rate of transfusion, the age of the transfused PRBC, and not transfusing a PRBC with a potassium level above 15 mmol/L, they accomplished to suggest a safe and easy way for preventing transfusion associated hyperkalemia.

Clinical Analysis of Risk Factors for Mortality in Type A Acute Aortic Dissection: A Single Study From China

Objective: Acute type A aortic dissection (ATAAD) is a fatal condition that requires emergency surgery. The aim of the present study was to determine pre- and intra-operative risk factors for in-hospital mortality in patients with ATAAD.Methods: Consecutive 313 patients with ATAAD who underwent emergency surgery at our hospital from February 2012 to February 2017 were enrolled in our study. Univariate and multivariate logistic regression analysis were performed to identify the pre-operative and intra-operative risk factors for in-hospital mortality.Results: Of the 313 patients, 32 patients (10.2%) died. Compared with survivors, non-survivors had higher heart rate, serum potassium level and EuroSCORE II, and higher incidence of moderate to severe pericardial effusion, supra-aortic vessels involvement, myocardial ischemia and lower-extremity ischemia. As for surgery-related factors, the duration of surgery and cardiopulmonary bypass time were longer in non-survivors than survivors. In addition, non-survivors were more likely to undergo coronary-artery bypass graft compared with survivors. On multivariate analysis, elevated plasma potassium level (OR: 43.0, 95% CI: 3.8–51.5, p &lt; 0.001), high incidence of supra-aortic vessels involvement (OR: 4.4, 95% CI: 1.5–7.0, p = 0.008) and lower-extremity ischemia (OR: 4.9, 95% CI: 1.6–6.9; p = 0.009), and longer duration of surgery (OR 6.0, 95% CI: 1.8–18.7, p = 0.000) and cardiopulmonary bypass time (OR: 3.7, 95% CI: 1.3–9.3, p = 0.001) were independently predictive of higher mortality in patients with ATAAD.Conclusions: Supra-aortic vessels involvement, lower-extremity ischemia and elevated plasma potassium level are independent predictors of mortality in patients with ATAAD. A significant decrease in duration of surgery and cardiopulmonary bypass time is helpful to improve survival of patients.